{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-23-000068","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2023-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.580204+00:00","generated_at":"2026-06-14T07:29:38.504826+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Arcutis Biotherapeutics shareholders re-elect three Class II directors, ratify EY, approve say-on-pay","bullets":["All three Class II directors elected: Heron (44.2M for), Krishnamohan (50.4M for), Watanabe (45.4M for).","Ratification of Ernst & Young as independent auditor for FY 2023 passed with 54.5M votes for, 358K against.","Non-binding advisory vote on named executive officer compensation approved with 43.8M for, 7.3M against.","Meeting held May 31, 2023; record date April 3, 2023 with 61,360,936 shares outstanding."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-23-000068","json":"https://secwatch.observer/filing/0001787306-23-000068.json","markdown":"https://secwatch.observer/filing/0001787306-23-000068.md","text":"https://secwatch.observer/filing/0001787306-23-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000068/0001787306-23-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000068/arqt-20230602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T07:29:38.504826+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c0aa9cab25075cefac1f6a797b07ea5673f1f6d","claim":"Arcutis Biotherapeutics, Inc. shareholders approved Election of three Class II directors to hold office until the 2026 annual meeting or until their respective successor is elected at the 2023-05-31 meeting.","evidence_excerpt":"Proposal 1. The election of three Class II directors to hold office until the 2026 annual meeting of stockholders or until their respective successor is elected: Nominee Votes for Votes withheld Broker Non-Votes Patrick J. Heron 44,208,982 6,933,977 3,771,693 Neha Krishnamohan 50,425,906 717,053 3,771,693 Todd Franklin Watanabe 45,416,267 5,726,692 3,771,693","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000068/0001787306-23-000068-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-31"}],"fact_type":"shareholder_vote"},{"claim_id":"a645db8bd4824a001a0b1610d8be6580474d455b","claim":"Arcutis Biotherapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers at the 2023-05-31 meeting.","evidence_excerpt":"Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers: Votes for Votes against Abstentions Broker Non-Votes 43,770,313 7,343,874 28,772 3,771,693","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000068/0001787306-23-000068-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-31"}],"fact_type":"shareholder_vote"},{"claim_id":"fedc86b5dc757d0d8dad8e02ea924d28b9c07f5c","claim":"Arcutis Biotherapeutics, Inc. shareholders approved Ratification of the selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-31 meeting.","evidence_excerpt":"Proposal 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023: Votes for Votes against Abstentions Broker Non-Votes 54,541,027 358,765 14,860 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000068/0001787306-23-000068-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-31"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}